Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age

Pediatric Infectious Disease Journal

Volumn 35, Issue 2, 2016, Pages e35-e47

  Izurieta, Patricia ^a   Uy Aragon, Mercy Jeane ^b   Dramé, Mamadou ^c   Vaughn, David W ^c  

^a GSK   (Belgium)

^b RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^c GLAXOSMITHKLINE   (United States)

Author keywords

children; H5N1; influenza; prepandemic; prime boost

Indexed keywords

ADJUVANT; ALPHA TOCOPHEROL; HEMAGGLUTININ; HEPATITIS A VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SQUALENE; ASO3B ADJUVANT; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; POLYSORBATE; VIRUS ANTIBODY;

ADOLESCENT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INJECTION SITE PAIN; IRRITABILITY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; SWELLING; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS STRAIN; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; NEUTRALIZATION TESTS; POLYSORBATES; SQUALENE; TREATMENT OUTCOME;

EID: 84955352763     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000968     Document Type: Article

References (32)

1. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep Wash DC 1974. 2010;125:16-26.
2. World Health Organisation. Pandemic (H1N1) 2009-Update 109, 2010 July. Report No: Update 109. Available at: http://www.who.int/csr/don/2010-07-16/en/index.html. Accessed December 16, 2014.
3. Walker WT, Faust SN. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines. 2010;9: 1385-1398.
4. World Health Organisation. H5N1 Avian Influenza: Timeline of Major Events, December 13, 2011. Available at: http://www.who.int/influenza/human-animal-interface/avian-influenza/H5N1-avian-influenza-update. pdf. Accessed December 16, 2014.
5. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO. Available at: http://www.who.int/influenza/human-animal-interface/H5N1-cumulative-table-archives/en/. Accessed February 12, 2014.
6. Update on human cases of influenza at the human-animal interface, 2012. Wkly Epidemiol Rec. 2013;88:137-144.
7. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase trial in adults. J Infect Dis. 2010;201:1644-1653.
8. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370: 580-589.
9. Chu DW, Hwang SJ, Lim FS, et al; H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine. 2009;27:7428-7435.
10. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011;203:1729-1738.
11. Diéz-Domingo J, Garcés-Sanchez M, Baldó J-M, et al. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J. 2010;29:e35-e46.
12. Janjua NZ, Skowronski DM, Hottes TS, et al. Transmission dynamics and risk factors for pandemic H1N1-related illness: outbreak investigation in a rural community of British Columbia, Canada. Influenza Other Respir Viruses. 2012;6:e54-e62.
13. Viboud C, Boëlle PY, Cauchemez S, et al. Risk factors of influenza transmission in households. Br J Gen Pract. 2004;54:684-689.
14. Hehme N, Engelmann H, Kuenzel W, et al. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 2004;103:163-171.
15. Kendal A, Pereira M, Skehel J. Hemagglutination inhibition. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Atlanta, Georgia: Centers for Disease Control and Prevention and Pan-American Health Organization; 1985.
16. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37:937-943.
17. Stephenson I, Wood JM, Nicholson KG, et al. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004;103:91-95.
18. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103:133-138.
19. Beyer WE, Palache AM, Baljet M, et al. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine. 1989;7:385-394.
20. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Wkly Epidemiol Rec. 2011;86:469-480.
21. De Vleeschauwer AR, Baras B, Kyriakis CS, et al. Efficacy of an AS03Aadjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs. Vaccine. 2012;30:5557-5563.
22. Gillard P, Caplanusi A, Knuf M, et al. An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respir Viruses. 2013;7:55-65.
23. Langley JM, Frenette L, Jeanfreau RJ, et al. Immunogenicity of a heterologous H5N1 influenza booster vaccine 6 or 18 months after primary vaccination in adults [abstract]. In: 49th Annual Meeting of the Infectious Diseases Society of America and the HIV Medicine Association. Boston, MA, October 20-23, 2011.
24. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open nonrandomised extension of a double-blind randomised primary study. Vaccine. 2010;28:849-857.
25. Risi G, Frenette L, Langley JM, et al. Immunological priming induced by a twodose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine. 2011;29:6408-6418.
26. Nolan T, Izurieta P, Lee BW, et al. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children< 3 years of age. J Infect Dis. 2014;210:1800-1810
27. Rockman S, Brown L. Pre-pandemic and pandemic influenza vaccines. Hum Vaccin. 2010;6:792-801.
28. Halder N, Kelso JK, Milne GJ. A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness. BMC Infect Dis. 2014;14:266.
29. Carmona A, Omenãca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine. 2010;28:5837-5844.
30. Garcia-Sicilia J, Gillard P, Carmona A, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine. 2011;29:4353-4361.
31. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ. 2010;340:c2649.
32. Kosalaraksa P, Jeanfrau R, Frenette L, et al. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase II/III randomized, placebo-controlled, observer-blind trial. J Infect Dis. 2015;211:801-810.